Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
S100A1: a multifaceted therapeutic target in cardiovascular disease.
Rohde D, Ritterhoff J, Voelkers M, Katus HA, Parker TG, Most P. Rohde D, et al. Among authors: ritterhoff j. J Cardiovasc Transl Res. 2010 Oct;3(5):525-37. doi: 10.1007/s12265-010-9211-9. Epub 2010 Jul 20. J Cardiovasc Transl Res. 2010. PMID: 20645037 Free PMC article. Review.
Gene therapy targets in heart failure: the path to translation.
Raake PW, Tscheschner H, Reinkober J, Ritterhoff J, Katus HA, Koch WJ, Most P. Raake PW, et al. Among authors: ritterhoff j. Clin Pharmacol Ther. 2011 Oct;90(4):542-53. doi: 10.1038/clpt.2011.148. Epub 2011 Aug 24. Clin Pharmacol Ther. 2011. PMID: 21866097 Free PMC article. Review.
Targeting S100A1 in heart failure.
Ritterhoff J, Most P. Ritterhoff J, et al. Gene Ther. 2012 Jun;19(6):613-21. doi: 10.1038/gt.2012.8. Epub 2012 Feb 16. Gene Ther. 2012. PMID: 22336719 Review.
S100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulation.
Most P, Lerchenmüller C, Rengo G, Mahlmann A, Ritterhoff J, Rohde D, Goodman C, Busch CJ, Laube F, Heissenberg J, Pleger ST, Weiss N, Katus HA, Koch WJ, Peppel K. Most P, et al. Among authors: ritterhoff j. Circ Res. 2013 Jan 4;112(1):66-78. doi: 10.1161/CIRCRESAHA.112.275156. Epub 2012 Oct 9. Circ Res. 2013. PMID: 23048072 Free PMC article.
Heart failure gene therapy: the path to clinical practice.
Pleger ST, Brinks H, Ritterhoff J, Raake P, Koch WJ, Katus HA, Most P. Pleger ST, et al. Among authors: ritterhoff j. Circ Res. 2013 Aug 30;113(6):792-809. doi: 10.1161/CIRCRESAHA.113.300269. Circ Res. 2013. PMID: 23989720 Review.
Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model.
Weber C, Neacsu I, Krautz B, Schlegel P, Sauer S, Raake P, Ritterhoff J, Jungmann A, Remppis AB, Stangassinger M, Koch WJ, Katus HA, Müller OJ, Most P, Pleger ST. Weber C, et al. Among authors: ritterhoff j. Gene Ther. 2014 Feb;21(2):131-8. doi: 10.1038/gt.2013.63. Epub 2013 Dec 5. Gene Ther. 2014. PMID: 24305416 Free PMC article.
S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4.
Rohde D, Schön C, Boerries M, Didrihsone I, Ritterhoff J, Kubatzky KF, Völkers M, Herzog N, Mähler M, Tsoporis JN, Parker TG, Linke B, Giannitsis E, Gao E, Peppel K, Katus HA, Most P. Rohde D, et al. Among authors: ritterhoff j. EMBO Mol Med. 2014 Jun;6(6):778-94. doi: 10.15252/emmm.201303498. Epub 2014 Apr 6. EMBO Mol Med. 2014. PMID: 24833748 Free PMC article.
24 results